Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and a major cause of cancer mortality. Chemotherapy resistance remains a major challenge for treating advanced CRC. Therefore, the identification of targets that induce drug resistance is a priority for the development of novel agents to overcome resistance. Dragon (also known as RGMb) is a member of the repulsive guidance molecule (RGM) family. We previously showed that Dragon expression increases with CRC progression in human patients. In the present study, we found that Dragon inhibited apoptosis and increased viability of CMT93 and HCT116 cells in the presence of oxaliplatin. Dragon induced resistance of xenograft tumor to oxaliplatinin treatment in mice. Mechanistically, Dragon inhibited oxaliplatin-induced JNK and p38 MAPK activation, and caspase-3 and PARP cleavages. Our results indicate that Dragon may be a novel target that induces drug resistance in CRC.

• Publication year

  2016

• Venue

  OncoTarget

• Publication date

  2016-06-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.18632/oncotarget.10338PMID 27384995PMCID 5216997
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• miR218-5p regulates the proliferation of gastric cancer cells by targeting TFF1 in an Erk1/2-dependent manner.

  2015cited by this paper
• Simultaneous fingerprint and high-wavenumber fiber-optic Raman spectroscopy improves in vivo diagnosis of esophageal squamous cell carcinoma at endoscopy

  2015influential reference
• Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways

  2015cited by this paper
• Targeting RAS–ERK signalling in cancer: promises and challenges

  2014cited by this paper
• Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer

  2014cited by this paper
• Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer

  2014cited by this paper
• Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis : anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction

  2014cited by this paper
• Dysregulation of JAM-A plays an important role in human tumor progression.

  2014cited by this paper
• Low junctional adhesion molecule A expression correlates with poor prognosis in gastric cancer.

  2014cited by this paper
• Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour–stroma interaction

  2013cited by this paper
• Dragon (Repulsive Guidance Molecule RGMb) Inhibits E-cadherin Expression and Induces Apoptosis in Renal Tubular Epithelial Cells*

  2013cited by this paper
• Cancer-Associated CD43 Glycoforms as Target of Immunotherapy

  2013cited by this paper
• Increased variance in germline allele-specific expression of APC associates with colorectal cancer.

  2012cited by this paper
• Low Expression of Junctional Adhesion Molecule A Is Associated with Metastasis and Poor Survival in Pancreatic Cancer

  2012cited by this paper
• K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy

  2012cited by this paper
• Dragon (Repulsive Guidance Molecule b) Inhibits IL-6 Expression in Macrophages

  2011cited by this paper
• Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates

  2010cited by this paper
• Dragon enhances BMP signaling and increases transepithelial resistance in kidney epithelial cells.

  2010cited by this paper
• Integrating molecular diagnostics into anticancer drug discovery

  2010cited by this paper
• Signal integration by JNK and p38 MAPK pathways in cancer development

  2009cited by this paper
• Antagonistic control of cell fates by JNK and p38-MAPK signaling

  2008cited by this paper
• Colon cancer in older adults.

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• A novel cell type-specific role of p38α in the control of autophagy and cell death in colorectal cancer cells

  2007cited by this paper
• Repulsive Guidance Molecule RGMa Alters Utilization of Bone Morphogenetic Protein (BMP) Type II Receptors by BMP2 and BMP4*

  2007cited by this paper
• Role of RGM coreceptors in bone morphogenetic protein signaling

  2007cited by this paper
• Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses

  2007cited by this paper
• Non-coding RNA.

  2006cited by this paper
• Coordinating ERK/MAPK signalling through scaffolds and inhibitors

  2005cited by this paper
• DRAGON, a Bone Morphogenetic Protein Co-receptor*

  2005cited by this paper
• Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis

  2005cited by this paper
• A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

  2004cited by this paper
• Targeting JNK for therapeutic benefit: from junk to gold?

  2003cited by this paper
• p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

  2003cited by this paper
• RGM is a repulsive guidance molecule for retinal axons

  2002cited by this paper
• ABC of colorectal cancer. Molecular basis for risk factors.

  2000cited by this paper

• MUC3A promotes the progression of colorectal cancer through the PI3K/Akt/mTOR pathway

  2022cites this paper
• MiR-17-5p Targets and Downregulates CADM2, Activating the Malignant Phenotypes of Colon Cancer Cells

  2022cites this paper
• Circular RNA_0001073 (circ_0001073) Suppresses The Progression of Non-Small Cell Lung Cancer via miR-582-3p/RGMB Axis

  2021cites this paper
• Repulsive Guidance Molecule b Deficiency Induces Gut Microbiota Dysbiosis and Increases the Susceptibility to Intestinal Inflammation in Mice

  2021cites this paper
• TGF‐β superfamily co‐receptors in cancer

  2021cites this paper
• Upregulated NTF4 in colorectal cancer promotes tumor development via regulating autophagy

  2020cites this paper
• A novel lncRNA-miRNA-mRNA competitive endogenous RNA network for uveal melanoma prognosis constructed by weighted gene co-expression network analysis.

  2020cites this paper
• Analysis of risk factors for colon cancer progression

  2019cites this paper
• Clinicopathological analysis of PD-L2 expression in colorectal cancer

  2018cites this paper
• MiR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1

  2018cites this paper
• Andrographolide enhanced 5-fluorouracil-induced antitumor effect in colorectal cancer via inhibition of c-MET pathway

  2017cites this paper
• Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells

  2017cites this paper
• Sanggenon C induces apoptosis of colon cancer cells via inhibition of NO production, iNOS expression and ROS activation of the mitochondrial pathway

  2017cites this paper
• Osteopontin Promotes Cell Migration and Invasion, and Inhibits Apoptosis and Autophagy in Colorectal Cancer by activating the p38 MAPK Signaling Pathway

  2017cites this paper
• TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer

  2016cites this paper